Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on November 15, 2023. The Company is incorporated in Delaware and its common stock (DRMA) and warrants (DRMAW) are listed on The Nasdaq Capital Market. The filing addresses a regulatory notice regarding continued listing compliance rather than operational or financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing status notification and contains no financial performance data.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq indicating non-compliance with the $1.00 Minimum Bid Price requirement (Nasdaq Listing Rule 5550(a)(2)). This non-compliance is based on the closing bid price of the Company's common stock remaining below $1.00 for 30 consecutive business days. This notice does not result in immediate delisting.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180 calendar days (until May 13, 2024) to regain compliance.
- Path to Compliance: Compliance can be achieved if the bid price closes at or above $1.00 per share for a minimum of ten consecutive business days during the compliance period.
- Alternative Options: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: Failure to regain compliance or qualify for an extension may lead to a delisting determination, which the Company may appeal to a hearings panel.
- Operational Impact: Management states that the receipt of the Notice does not affect the Company's business, operations, or SEC reporting requirements.
Investor Verification Checklist
- Verify the current closing bid price of DRMA to assess proximity to the $1.00 threshold.
- Monitor Company announcements regarding the potential execution of a reverse stock split.
- Review the Company's cash position in other filings (e.g., 10-K, 10-Q) to determine if capital raises are needed to support operations while addressing the listing issue.
- Check for any subsequent 8-K filings confirming compliance or detailing the appeal process if the initial 180-day period expires.